Clinical Importance and Epidemiology of Quinolone Resistance

키워드

참고문헌 (124)

1. Hawkey PM, "Mechanisms of quinolone action and microbial response", J Antimicrob Chemother, 51(Suppl 1), pp.29~35 (2003)
2. Jacoby GA, "Mechanisms of resistance to quinolones", Clin Infect Dis, 41(Suppl 2), pp.S120~S126 (2005)
3. Hiasa H, "DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex", J Biol Chem, 275, pp.34780~34786 (2000)
4. Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America", Clin Infect Dis, 52, pp.427~431 (2011)
5. Bratzler DW, "Clinical practice guidelines for antimicrobial prophylaxis in surgery", Am J Health Syst Pharm, 70, pp.195~283 (2013)
6. Neuhauser MM, "Antibiotic resistance among gramnegative bacilli in US intensive care units: implications for fluoroquinolone use", JAMA, 289, pp.885~888 (2003)
7. 전강일, "일개 대학병원의 항생제 사용양상 변화(2001-2012)", 병원감염관리, 18(2), pp.44~50 (2013), 대한의료관련감염관리학회
8. vin-Eliopoulos C, "Quinolone Antimicrobial Agents. 3rd ed", pp.91~111 (2003), American Society for Microbiology Press
9. Hooper DC, "Quinolone Antimicrobial Agents. 3rd ed", pp.41~67 (2003), American Society for Microbiology Press
10. Yoshida H, "Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli", Antimicrob Agents Chemother, 34, pp.1271~1272 (1990)
11. Friedman SM, "Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region", Antimicrob Agents Chemother, 45, pp.2378~2380 (2001)
12. Barnard FM, "Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87)", Antimicrob Agents Chemother, 45, pp.1994~2000 (2001)
13. Willmott CJ, "A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex", Antimicrob Agents Chemother, 37, pp.126~127 (1993)
14. Ng EY, "Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus", Antimicrob Agents Chemother, 40, pp.1881~1888 (1996)
15. Eliopoulos GM, "Quinolone resistance mechanisms in pneumococci", Clin Infect Dis, 38, pp.S350~S356 (2004)
16. Poole K, "Efflux-mediated antimicrobial resistance", J Antimicrob Chemother, 56, pp.20~51 (2005)
17. Wang H, "Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations", Antimicrob Agents Chemother, 45, pp.1515~1521 (2001)
18. Alekshun MN, "Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon", Antimicrob Agents Chemother, 41, pp.2067~2075 (1997)
19. Cohen SP, "Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction", Antimicrob Agents Chemother, 33, pp.1318~1325 (1989)
20. Thanassi DG, "Active efflux of bile salts by Escherichia coli", J Bacteriol, 179, pp.2512~2518 (1997)
21. Zhanel GG, "Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa", Int J Antimicrob Agents, 24, pp.529~535 (2004)
22. Kosmidis C, "Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus", Int J Antimicrob Agents, 40, pp.204~209 (2012)
23. Kwak YG, "Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68, pp.2766~2772 (2013), OXFORD UNIV PRESS
24. Martínez-Martínez L, "Quinolone resistance from a transferable plasmid", Lancet, 351, pp.797~799 (1998)
25. Rodríguez-Martínez JM, "Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase", J Antimicrob Chemother, 52, pp.703~706 (2003)
26. Wang M, "Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States", Antimicrob Agents Chemother, 48, pp.1295~1299 (2004)
27. Wang M, "Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China", Antimicrob Agents Chemother, 47, pp.2242~2248 (2003)
28. Cheung TK, "Plasmid-mediated resistance to ciprofloxacin and cefotaxime in clinical isolates of Salmonella enterica serotype Enteritidis in Hong Kong", J Antimicrob Chemother, 56, pp.586~589 (2005)
29. Hata M, "Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b", Antimicrob Agents Chemother, 49, pp.801~803 (2005)
30. Jacoby GA, "qnrB, another plasmid-mediated gene for quinolone resistance", Antimicrob Agents Chemother, 50, pp.1178~1182 (2006)
31. Wang M, "New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis", Antimicrob Agents Chemother, 53, pp.1892~1897 (2009)
32. Cavaco LM, "qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin", Antimicrob Agents Chemother, 53, pp.603~608 (2009)
33. Xia R, "qnrVC-like gene located in a novel complex class 1 integron harboring the ISCR1 element in an Aeromonas punctata strain from an aquatic environment in Shandong Province, China", Antimicrob Agents Chemother, 54, pp.3471~3474 (2010)
34. Singh R, "Clinical isolates of Vibrio fluvialis from Kolkata, India, obtained during 2006: plasmids, the qnr gene and a mutation in gyrase A as mechanisms of multidrug resistance", J Med Microbiol, 61, pp.369~374 (2012)
35. Fonseca EL, "Epidemiology of qnrVC alleles and emergence out of the Vibrionaceae family", J Med Microbiol, 62, pp.1628~1630 (2013)
36. Kim HB, "Transferable quinolone resistance in Vibrio cholerae", Antimicrob Agents Chemother, 54, pp.799~803 (2010)
37. Robicsek A, "Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase", Nat Med, 12, pp.83~88 (2006)
38. Strahilevitz J, "Plasmid-mediated quinolone resistance: a multifaceted threat", Clin Microbiol Rev, 22, pp.664~689 (2009)
39. Hansen LH, "Plasmid-encoded multidrug efflux pump conferring resistance to olaquindox in Escherichia coli", Antimicrob Agents Chemother, 48, pp.3332~3337 (2004)
40. Yamane K, "New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate", Antimicrob Agents Chemother, 51, pp.3354~3360 (2007)
41. Schito GC, "The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections", Int J Antimicrob Agents, 34, pp.407~413 (2009)
42. Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
43. Hooton TM, "Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.625~663 (2010)
44. Zhanel GG, "Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)", Int J Antimicrob Agents, 27, pp.468~475 (2006)
45. Lu PL, "Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)", Int J Antimicrob Agents, 40(Suppl), pp.S37~S43 (2012)
46. Lee MY, "Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea", JOURNAL OF INFECTION, 60(2), pp.146~153 (2010), W B SAUNDERS CO LTD
47. Kim Y, "Comparison of the Clinical Characteristics of Diabetic and Non-diabetic Women with Community-Acquired Acute Pyelonephritis: A Multicenter Study", J INFECT, 69(3), pp.244~251 (2014), SAUNDERS
48. Park KH, "Factors associated with ciprofloxacin-and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department", Int J Infect Dis, 23, pp.8~13 (2014)
49. Chaniotaki S, "Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece", Clin Microbiol Infect, 10, pp.75~78 (2004)
50. Killgore KM, "Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection", Ann Pharmacother, 38, pp.1148~1152 (2004)
51. Arslan H, "Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey", J Antimicrob Chemother, 56, pp.914~918 (2005)
52. Johnson L, "Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates", Am J Med, 121, pp.876~884 (2008)
53. van der Starre WE, "Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection", J Antimicrob Chemother, 66, pp.650~656 (2011)
54. Vellinga A, "Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model", J Antimicrob Chemother, 67, pp.2523~2530 (2012)
55. Colodner R, "Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli", Infection, 36, pp.41~45 (2008)
56. Cizman M, "Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections", J Antimicrob Chemother, 47, pp.502~ (2001)
57. Zervos MJ, "Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000", Clin Infect Dis, 37, pp.1643~1648 (2003)
58. MacDougall C, "Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals", Clin Infect Dis, 41, pp.435~440 (2005)
59. Mahamat A, "Evaluation of the relation between consumption of fluoroquinolones and emergence of resistance among Escherichia coli: contribution of observational and quasi-experimental studies", Med Mal Infect, 35, pp.543~548 (2005)
60. Gallini A, "Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital", J Antimicrob Chemother, 65, pp.2650~2657 (2010)
61. Paterson DL, "Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia", Clin Infect Dis, 30, pp.473~478 (2000)
62. Hsueh PR, "Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region", J Infect, 63, pp.114~123 (2011)
63. Lee SS, "Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis", JOURNAL OF INFECTION, 62(2), pp.159~164 (2011), W B SAUNDERS CO LTD
64. Jeon JH, "Empirical Use of Ciprofloxacin for Acute Uncomplicated Pyelonephritis Caused by Escherichia coli in Communities Where the Prevalence of Fluoroquinolone Resistance Is High", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), pp.3043~3046 (2012), AMER SOC MICROBIOLOGY
65. Chen YH, "The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens", Eur J Clin Microbiol Infect Dis, 31, pp.1699~1704 (2012)
66. Mandell LA, "Infectious Diseases Society of America", American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, 2007, pp.Suppl 2, S27~S72
67. 송재훈, "지역사회획득 폐렴의 치료지침 권고안", Infection and Chemotherapy, 41(3), pp.133~153 (2009), 대한감염학회
68. Low DE, "Quinolone resistance among pneumococci: therapeutic and diagnostic implications", Clin Infect Dis, 38(Suppl 4), pp.S357~S362 (2004)
69. Jenkins SG, "Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US years 1-4", Ann Clin Microbiol Antimicrob, 7, pp.1~ (2008)
70. Patel SN, "Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada", Antimicrob Agents Chemother, 55, pp.3703~3708 (2011)
71. "Antimicrobial resistance surveillance in Europe 2012"[URL]
72. Jacobs E, "Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study)", Int J Antimicrob Agents, 33, pp.52~57 (2009)
73. Pletz MW, "Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage", Int J Med Microbiol, 301, pp.53~57 (2011)
74. Kim SH, "Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP)study", Antimicrob Agents Chemother, 56, pp.1418~1426 (2012)
75. Jiménez MR, "Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients", J Clin Microbiol, 43, pp.1193~1197 (2005)
76. Ho PL, "Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study", Clin Infect Dis, 32, pp.701~707 (2001)
77. Kang CI, "Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study", Eur J Clin Microbiol Infect Dis, 33, pp.55~59 (2014)
78. Kang CI, "Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort", Infection, 41, pp.151~157 (2013)
79. de Cueto M, "Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation", J Clin Microbiol, 46, pp.1558~1560 (2008)
80. Pfaller MA, "AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States", Clin Infect Dis, 55(Suppl 3), pp.S187~S193 (2012)
81. Chung DR, "High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 184(12), pp.1409~1417 (2011), AMER THORACIC SOC
82. Karlowsky JA, "Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001", Antimicrob Agents Chemother, 47, pp.1681~1688 (2003)
83. Jones ME, "Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002)", Ann Clin Microbiol Antimicrob, 3, pp.14~ (2004)
84. Perez F, "Global challenge of multidrug-resistant Acinetobacter baumannii", Antimicrob Agents Chemother, 51, pp.3471~3484 (2007)
85. Lagamayo EN, "Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries", Am J Infect Control, 36(4 Suppl), pp.S101~S108 (2008)
86. Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
87. Babinchak T, "Trends in susceptibility of selected gramnegative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010", Diagn Microbiol Infect Dis, 76, pp.379~381 (2013)
88. Hawser SP, "Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)", Antimicrob Agents Chemother, 54, pp.3043~3046 (2010)
89. Bochicchio GV, "In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)", Surg Infect (Larchmt), 7, pp.537~545 (2006)
90. Ko WC, "Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia", Pacific region: data from the smart study 2002-2006, 2009, pp.59, 95~103
91. Yang Q, "Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART)", Int J Antimicrob Agents, 36, pp.507~512 (2010)
92. Kang CI, "Risk factors for mortality and impact of broad-spectrum cephalosporin resistance on outcome in bacteraemic intra-abdominal infections caused by Gram-negative bacilli", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 43(3), pp.202~208 (2011), INFORMA HEALTHCARE
93. Yagci D, "Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy", Antimicrob Agents Chemother, 53, pp.1287~1289 (2009)
94. Garau J, "Emergence and dissemination of quinolone-resistant Escherichia coli in the community", Antimicrob Agents Chemother, 43, pp.2736~2741 (1999)
95. Nagy E, "Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience", Clin Microbiol Infect, 17, pp.371~379 (2011)
96. Low DE, "Quinolone Antimicrobial Agents. 3rd ed", pp.355~386 (2003), American Society for Microbiology Press
97. Parry CM, "Antimicrobial resistance in typhoidal and nontyphoidal salmonellae", Curr Opin Infect Dis, 21, pp.531~538 (2008)
98. Gu B, "Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009", Int J Antimicrob Agents, 40, pp.9~17 (2012)
99. Horiuchi S, "Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones", Antimicrob Agents Chemother, 37, pp.2486~2489 (1993)
100. Vinh H, "Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid", Trans R Soc Trop Med Hyg, 94, pp.323~326 (2000)
101. Khan WA, "Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial", Ann Intern Med, 126, pp.697~703 (1997)
102. Ge B, "Antimicrobial resistance in Campylobacter: susceptibility testing methods and resistance trends", J Microbiol Methods, 95, pp.57~67 (2013)
103. Shin E, "Antimicrobial resistance patterns and corresponding multilocus sequence types of the Campylobacter jejuni isolates from human diarrheal samples", Microb Drug Resist, 19, pp.110~116 (2013)
104. Goodman LJ, "Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults", Arch Intern Med, 150, pp.541~546 (1990)
105. Kuschner RA, "Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent", Clin Infect Dis, 21, pp.536~541 (1995)
106. Karchmer AW, "Quinolone Antimicrobial Agents. 3rd ed", pp.311~321 (2003), American Society for Microbiology Press
107. Dalhoff A, "Resistance surveillance studies: a multifaceted problem-the fluoroquinolone example", Infection, 40, pp.239~262 (2012)
108. Montes M, "Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain", Antimicrob Agents Chemother, 54, pp.93~97 (2010)
109. Van Heirstraeten L, "Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10", J Antimicrob Chemother, 67, pp.2602~2605 (2012)
110. Barry AL, "In vitro activity of ciprofloxacin against gram-positive cocci", Am J Med, 82, pp.27~32 (1987)
111. Smith SM, "In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus", Antimicrob Agents Chemother, 29, pp.325~326 (1986)
112. Flamm RK, "LEADER surveillance program results for 2010:an activity and spectrum analysis of linezolid using 6801clinical isolates from the United States (61 medical centers)", Diagn Microbiol Infect Dis, 74, pp.54~61 (2012)
113. Kim ES, "Molecular Characterization of Methicillin-Resistant Staphylococcus aureus Isolates in Korea", JOURNAL OF CLINICAL MICROBIOLOGY, 49, pp.1979~1982 (2011), AMER SOC MICROBIOLOGY
114. Jones RN, "Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study", J Antimicrob Chemother, 65(Suppl 4), pp.iv17~iv31 (2010)
115. Naimi TS, "Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection", JAMA, 290, pp.2976~2984 (2003)
116. Moran GJ, "Methicillin-resistant S. aureus infections among patients in the emergency department", N Engl J Med, 355, pp.666~674 (2006)
117. Mendes RE, "Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid", J Clin Microbiol, 48, pp.568~574 (2010)
118. Lipsky BA, "2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections", Clin Infect Dis, 54, pp.e132~e173 (2012)
119. Kim BN, "Oral antibiotic treatment of staphylococcal bone and joint infections in adults", J Antimicrob Chemother, 69, pp.309~322 (2014)
120. Stevens DL, "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.147~159 (2014)
121. "Antibiotic-resistant gonorrhea basic information"[URL]
122. Lee H, "Trends in antimicrobial resistance of neisseria gonorrhoeae isolated from Korean patients from 2000 to 2006", SEXUALLY TRANSMITTED DISEASES, 38(11), pp.1082~1086 (2011), LIPPINCOTT WILLIAMS & WILKINS
123. Rahman M, "Treatment failure with the use of ciprofloxacin for gonorrhea correlates with the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae strains in Bangladesh", Clin Infect Dis, 32, pp.884~889 (2001)
124. Workowski KA, "Sexually transmitted diseases treatment guidelines, 2010", MMWR Recomm Rep, 59, pp.1~110 (2010)

관련 논문AI추천